![Adesh Kaul](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Adesh Kaul
Directeur Financier/CFO chez
BASILEA PHARMACEUTICA AG
Fortune : 1 M $ au 31/05/2026
Profil
Currently, Adesh Kaul is Chief Financial Officer at Basilea Pharmaceutica AG since 2019, with employment at the firm starting in 2009.
Formerly, Mr. Kaul was CFO & Head-Corporate Development at Spexis Ltd. from 2015 to 2016.
Also worked as a Research Analyst at NZB Neue Zürcher Bank AG (Investment Management) and NZB Neue Zürcher Bank AG.
Education includes an MBA from the University of St. Gallen and a graduate degree from the University of Basel.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BASILEA PHARMACEUTICA AG 0,12 % | 31/12/2025 | 16 205 ( 0,12 % ) | 1 M $ | 31/05/2026 |
Postes actifs de Adesh Kaul
| Sociétés | Poste | Début |
|---|---|---|
| BASILEA PHARMACEUTICA AG | Directeur Financier/CFO | 10/04/2019 |
Anciens postes connus de Adesh Kaul
| Sociétés | Poste | Fin |
|---|---|---|
| SPEXIS AG | Directeur Financier/CFO | 01/01/2016 |
NZB Neue Zürcher Bank AG (Investment Management)
 NZB Neue Zürcher Bank AG (Investment Management) Major BanksFinance NZB-IM is an active manager which follows a top-down approach. Their investment focus is on the Swiss market. The investment managers use both quantitative and qualitative factors to construct value-oriented portfolios for long-term returns. In addition to their in-house team, they utilize external sources such as experts in taxation, legal, estate- and retirement-planning. | Analyst-Equity | - |
NZB Neue Zürcher Bank AG
 NZB Neue Zürcher Bank AG Investment Banks/BrokersFinance Provides securities and brokerage services | Analyst-Equity | - |
Formation de Adesh Kaul
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
28
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
NZB Neue Zürcher Bank AG (Investment Management)
NZB Neue Zürcher Bank AG (Investment Management) Major BanksFinance NZB-IM is an active manager which follows a top-down approach. Their investment focus is on the Swiss market. The investment managers use both quantitative and qualitative factors to construct value-oriented portfolios for long-term returns. In addition to their in-house team, they utilize external sources such as experts in taxation, legal, estate- and retirement-planning. | Finance |
Basilea Pharmaceutica AG
 Basilea Pharmaceutica AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
University of St. Gallen
 University of St. Gallen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Basel
 University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Spexis Ltd.
 Spexis Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that focuses on the discovery and development of macrocycle drugs addressing unmet medical needs | Health Technology |
NZB Neue Zürcher Bank AG
NZB Neue Zürcher Bank AG Investment Banks/BrokersFinance Provides securities and brokerage services | Finance |
